title: Sunitinib still fi rst-line therapy for metastatic renal cancer.
authors.forename: Sanjeet
authors.initials: S
authors.lastname: Bagcchi
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000401:mortality / Q000556:secondary; D018572:Disease-Free Survival; D000068338:Everolimus; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D009362:Neoplasm Metastasis; D011379:Prognosis; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects; D018570:Risk Assessment; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077210:Sunitinib; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000068338:Everolimus; D007211:Indoles; D011758:Pyrroles; D020123:Sirolimus; D000077210:Sunitinib